10-Q: Atai Beckley Reports Q3 Losses Amid Pipeline Progress, Capital Boost

Atai Beckley N.V. reported increased net losses for Q3 2025, driven by higher operating expenses, but secured significant capital and advanced its psychedelic-based neuroplastogen pipeline, including a Breakthrough Therapy designation for BPL-003.

Summary

• Net loss attributable to Atai Beckley N.V. stockholders increased to $61.074 million for the three months ended September 30, 2025, compared to $26.286 million for the same period in 2024.
• Total revenue for the nine months ended September 30, 2025, significantly increased to $3.023 million from $0.313 million in 2024, primarily due to research and development services revenue from the Nualtis acquisition.
• Research and development expenses slightly increased to $37.100 million for the nine months ended September 30, 2025, from $36.513 million in 2024, reflecting increased clinical development costs for VLS-01 and EMP-01, and a $3.0 million Psilera milestone payment.
• General and administrative expenses rose to $40.002 million for the nine months ended September 30, 2025, up from $36.226 million in 2024, largely due to legal and professional service expenses related to the Beckley Psytech strategic combination and pending Redomiciliation.
• The company completed a strategic combination with Beckley Psytech Limited on November 5, 2025, and subsequently changed its name to Atai Beckley N.V.
• BPL-003 received Breakthrough Therapy designation from the FDA and reported positive topline results from its eight-week OLE phase of the Phase 2b clinical trial for treatment-resistant depression (TRD).
• Patient enrollment was completed for the exploratory Phase 2a study of EMP-01 for social anxiety disorder (SAD), with topline results anticipated in Q1 2026.
• The Elumina Phase 2 trial for VLS-01 in TRD continued enrollment in the US and expanded to Australia and the United Kingdom, with topline data expected in H2 2026.
• A multi-year, milestone-driven grant worth up to $11.4 million was awarded by the National Institute on Drug Abuse (NIDA) to fund the optimization and early-stage development of novel 5-HT2A/2C receptor agonists for opioid use disorder (OUD).
• The company successfully raised significant capital through a February 2025 public offering ($59.1 million net), June 2025 PIPE Financing ($28.1 million net), July 2025 PIPE Financing ($46.7 million net), and an October 2025 public offering ($139.4 million net).
• The Hercules Term Loan Facility, with an outstanding amount of approximately $21.8 million, was fully paid off in May 2025, resulting in a $1.3 million loss on extinguishment of debt.
• The company's cash, cash equivalents, and short-term securities are expected to fund operations into 2029, inclusive of the October 2025 public offering proceeds.
• The Board of Directors approved a redomiciliation to Delaware, with shareholder approval obtained in November 2025, and completion expected around year-end 2025.
• Workforce reductions of approximately 25% in March 2025 and 10% in February 2024 were implemented to reduce operational costs and extend cash runway.

Sentiment

Score: 6

Explanation: The company reported increased net losses and operating expenses, indicating continued financial challenges typical of a clinical-stage biopharmaceutical company. However, significant capital raises, positive clinical trial progress for BPL-003 (including Breakthrough Therapy designation), and strategic corporate actions like the Beckley Psytech combination and planned redomiciliation provide a strong foundation for future development and extend the cash runway significantly. The overall sentiment is cautiously optimistic, balancing current losses with strong strategic and clinical advancements.

Positives

• BPL-003 received Breakthrough Therapy designation from the FDA, indicating its potential to offer substantial improvement over existing therapies for TRD.
• Positive topline results were reported from the eight-week OLE phase of the Phase 2b clinical trial of BPL-003, showing additional clinically meaningful antidepressant effects sustained for at least two months.
• The company secured significant capital through multiple offerings, including a February 2025 public offering ($59.1 million net), June 2025 PIPE Financing ($28.1 million net), July 2025 PIPE Financing ($46.7 million net), and an October 2025 public offering ($139.4 million net).
• The Hercules Term Loan Facility of approximately $21.8 million was fully paid off in May 2025, eliminating associated interest expenses and debt obligations.
• The company's existing cash, cash equivalents, and short-term securities, combined with recent capital raises, are projected to fund operations into 2029, providing a long cash runway.
• A multi-year, milestone-driven grant of up to $11.4 million was awarded by NIDA for the development of novel 5-HT2A/2C receptor agonists for opioid use disorder (OUD), providing non-dilutive funding.
• The acquisition of Nualtis Corp. (formerly IntelGenx Corp.) in October 2024 and its subsequent rebranding in June 2025 has diversified revenue streams through research and development services.
• Novel non-hallucinogenic 5-HT2A receptor agonists have been discovered, expanding the drug discovery program with differentiated therapeutic potential.

Negatives

• Net loss attributable to Atai Beckley N.V. stockholders increased to $61.074 million for the three months ended September 30, 2025, from $26.286 million in the prior year period, and to $115.234 million for the nine months ended September 30, 2025, from $110.311 million in 2024.
• General and administrative expenses increased significantly, primarily due to legal and professional fees associated with the Beckley Psytech strategic combination and the pending Redomiciliation.
• The Otsuka License and Collaboration Agreement was terminated in January 2025, effective April 2025, eliminating future milestone payments or royalties from this agreement.
• The company incurred a $1.3 million loss on extinguishment of debt due to the early repayment of the Hercules Term Loan Facility.
• Workforce reductions of approximately 25% in March 2025 and 10% in February 2024 indicate ongoing efforts to control costs, which can impact morale and operational continuity.
• The company continues to incur significant losses and negative cash flows from operations, with no revenue generated from the sale of core product candidates to date.

Risks

• The combined group will incur losses for the foreseeable future and might never achieve profitability, requiring successful completion of significant research, development, testing, and regulatory compliance activities.
• Failure to realize the anticipated benefits of the strategic combination with Beckley Psytech, including expected synergies, cost savings, and successful clinical, regulatory, and commercial outcomes for Beckley Psytech's product candidates.
• Challenges with the integration of the businesses and operations of atai and Beckley Psytech, potentially leading to loss of suppliers, vendors, partners, disruption of ongoing businesses, inconsistencies in standards, unforeseen expenses, or delays.
• The expected benefits of the Redomiciliation to Delaware may not be realized, and the process itself may be delayed or not implemented due to creditor opposition, litigation, or unforeseen regulatory requirements.
• Clinical trials are inherently uncertain, and preliminary or early-stage results may not be predictive of final outcomes or lead to regulatory approval.
• The production and sale of product candidates may be considered illegal or restricted due to the use of controlled substances, potentially impacting commercialization in certain jurisdictions.
• Significant competition in an environment of rapid technological and scientific change, with competitors potentially achieving regulatory approval sooner or developing superior therapies.
• Inability to obtain and maintain sufficient intellectual property protection for existing or future product candidates, or claims of infringement from third parties.
• Dependence on key employees, directors, consultants, and advisors, with future success relying on the ability to retain and attract qualified personnel.
• Failure to maintain an effective system of disclosure controls and internal control over financial reporting could impair the ability to produce timely and accurate financial statements.

Future Outlook

The company anticipates providing guidance on the BPL-003 Phase 3 clinical program in the first quarter of 2026, with Phase 3 trial initiation expected in the second quarter of 2026, pending FDA meeting outcomes. Topline data from the VLS-01 Elumina trial is expected in the second half of 2026, and topline results from the EMP-01 exploratory Phase 2a study are anticipated in the first quarter of 2026. The redomiciliation to Delaware is expected around year-end 2025, aiming to improve operational and financial flexibility. The company expects to incur losses for the foreseeable future until product candidates are commercialized, but projects its current capital to fund operations into 2029.

Management Comments

• Our work is grounded in rigorous science to deliver meaningful outcomes for the patients we serve.
• We are committed to leading a new era of mental health treatment – one that not only offers relief from symptoms, but the possibility of an improved quality of life and lasting change.
• We believe psychedelics are emerging as novel breakthrough therapies for mental health disorders, such as depression, supported by growing scientific evidence, recent regulatory advancements and increasing patient and physician acceptance.
• We are committed to innovation in the mental health space as exemplified by our drug discovery program and its focus on identifying new molecules with psychedelic-like pharmacology but without hallucinogenic potential.

Industry Context

Atai Beckley operates in the rapidly evolving biopharmaceutical industry, specifically targeting difficult-to-treat mental health conditions with a focus on psychedelic and non-psychedelic neuroplastogens. The industry is seeing growing scientific support and regulatory advancements for psychedelics as novel therapies, offering rapid onset and sustained efficacy. The company's diversified pipeline and drug discovery efforts align with the broader trend of seeking innovative solutions beyond traditional treatments like SSRIs and SNRIs, which often fail to achieve remission for a significant portion of patients. The substantial economic burden of mental health disorders, projected to reach $16 trillion by 2030, underscores the urgent unmet medical need that Atai Beckley aims to address.

Comparison to Industry Standards

• BPL-003's Breakthrough Therapy designation by the FDA positions it favorably against other emerging therapies for Treatment-Resistant Depression (TRD), suggesting a potential for substantial improvement over existing treatments, similar to how other novel therapies have been fast-tracked in areas of high unmet need.
• The company's focus on psychedelic-based neuroplastogens, including DMT and R-MDMA, places it at the forefront of a nascent but rapidly growing segment of mental health therapeutics, differentiating it from traditional pharmaceutical companies that primarily develop small molecule or biologic drugs.
• The NIDA grant for novel 5-HT2A/2C receptor agonists for Opioid Use Disorder (OUD) highlights the company's engagement in addressing significant public health crises, aligning with broader industry and governmental efforts to combat the opioid epidemic, potentially comparable to initiatives by companies like Indivior or Braeburn Pharmaceuticals in the addiction space.
• While direct comparisons to specific competitors' clinical trial results are not provided, the positive topline data for BPL-003 in TRD suggests competitive progress within the psychedelic-assisted therapy landscape, where companies like COMPASS Pathways (with psilocybin for TRD) are also advancing late-stage programs.

Corporate Governance

Legal Proceedings

• The company is, from time to time, party to various claims and legal proceedings arising in the ordinary course of business. No demands have been made upon the company to provide indemnification under such agreements, and no claims are aware of that could have a material effect on the company's consolidated financial statements.

Related Party Transactions

• Apeiron Investment Group Ltd. (family office of Christian Angermayer, Co-Founder and Chairman) owns 23.0% of outstanding common stock as of September 30, 2025.
• Consulting Agreement with Mr. Angermayer was extended to January 5, 2028, and new stock options were granted in June 2025.
• Apeiron participated in the February 2025 public offering, purchasing 10,835,718 common shares for $2.10 per share.
• Apeiron participated in the July 2025 PIPE Financing, purchasing 8,675,799 common shares for $2.19 per share.
• Apeiron, as a related party noteholder, converted its New NV Notes into 2,367,200 common shares in September 2025.
• The company issued an unsecured promissory note in the principal amount of $10.0 million to Beckley Psytech in August 2025, with net proceeds for product development milestones.

Stakeholder Impact

• Shareholders: Experience dilution from multiple equity offerings but benefit from a significantly extended cash runway into 2029 and potential long-term value from pipeline advancements and strategic combinations. Face risks related to integration challenges and redomiciliation.
• Employees: Affected by workforce reductions (25% in March 2025, 10% in February 2024) but also benefit from stock-based compensation plans and the potential for growth within the combined entity.
• Customers/Patients: The company's focus on developing rapid-acting, effective, and durable mental health treatments, including psychedelic and non-psychedelic compounds, aims to address significant unmet medical needs for patients with difficult-to-treat mental health conditions.
• Creditors: The Hercules Term Loan Facility was fully paid off, reducing debt obligations. However, potential creditor opposition to the redomiciliation could cause delays.
• Suppliers/Partners: The integration of Beckley Psytech's businesses carries a risk of disruption or loss of existing supplier and vendor relationships.

Next Steps

• Schedule an End-of-Phase 2 meeting with the FDA to align on clinical trial designs and other aspects of the BPL-003 Phase 3 development program.
• Provide guidance on the BPL-003 Phase 3 clinical program in the first quarter of 2026.
• Initiate BPL-003 Phase 3 trials in the second quarter of 2026, pending the outcome of the FDA meeting.
• Continue enrollment in the VLS-01 Elumina Phase 2 trial in the US, Australia, and the United Kingdom.
• Release topline data from the VLS-01 Elumina trial in the second half of 2026.
• Release topline results from the EMP-01 exploratory Phase 2a study in the first quarter of 2026.
• Further optimize and study novel non-hallucinogenic 5-HT2A receptor agonists in a series of animal models to assess therapeutic potential.
• Complete the Redomiciliation to Delaware around year-end 2025, following shareholder approval of the LuxCo Merger.

Key Dates

Recommendation

Atai Beckley N.V. presents a mixed financial picture with increased net losses for the period, reflecting the high R&D costs typical of a clinical-stage biopharmaceutical company. However, the company has significantly bolstered its liquidity through multiple successful capital raises, extending its cash runway into 2029. Key clinical programs, particularly BPL-003, show promising progress with an FDA Breakthrough Therapy designation and positive Phase 2b results, indicating potential for future value creation. The strategic combination with Beckley Psytech and the planned redomiciliation are transformative steps, but also introduce integration and execution risks. Given the early-stage nature of most programs, the long path to profitability, and the inherent uncertainties of drug development, a 'Hold' recommendation is appropriate. Investors should monitor the successful integration of Beckley Psytech, the progress of BPL-003 into Phase 3, and the outcomes of other clinical trials, as these will be critical determinants of future stock performance.

Keywords

psychedelics, mental health, biopharmaceutical, clinical trials, TRD, SAD, DMT, MDMA, 5-HT2A receptor agonists, neuroplastogens, Beckley Psytech, Nualtis, SEC filing, 10-Q, capital raise, redomiciliation, biotech, drug development, FDA Breakthrough Therapy